Fasted Bioavailability Study of Cilostazol Tablets, 100 mg

NCT ID: NCT00684762

Last Updated: 2009-12-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-03-31
• Study Completion Date: 2004-03-31

Brief Summary

The purpose of this study is to evaluate and compare the relative bioavailability of a test formulation of cilostazol tablets to an equivalent dose of Pletal® (cilostazol) tablets after a single oral dose administered under fasting conditions.

Detailed Description

The purpose of this study is to evaluate and compare the relative bioavailability of a test formulation of cilostazol tablets to an equivalent dose of Pletal® (cilostazol) tablets after a single oral dose administered under fasting conditions. Thirty-two non-smoking, non-obese, healthy male and female volunteers between the ages of 18 and 55 will be randomly assigned in a crossover fashion to receive each of two cilostazol dosing regimens in sequence with a 7 day washout period between dosing periods. On the morning of Day 1, after an overnight fast of at least 10 hours, subjects will receive either a single oral dose of the test formulation, cilostazol (1 x 100 mg tablet), or a single oral dose of the reference formulation, Pletal® (1 x 100 mg tablet). After a 7 day washout period on the morning of Day 8, following an overnight fast of at least 10 hours, subjects will receive the alternate regimen. Blood samples will be drawn from all participants before dosing and for 24 hours post-dose on a confined basis at times sufficient to adequately define the pharmacokinetics of cilostazol. Blood sampling will then continue on a non-confined basis at 36 and 48 hours post-dose. A further goal of this study is to evaluate the safety and tolerability of this regimen in healthy volunteers. Subjects will be monitored throughout the confinement portion of the study for adverse reactions to the study drug and/or procedures. Blood pressure and pulse will be measured before dosing and at 3 and 24 hours post-dose. All adverse events whether elicited by query, spontaneously reported, or observed by clinic staff will be evaluated by the investigator and reported in the subject's case report form.

Conditions

Therapeutic Equivalency

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Cilostazol

A single dose of cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours.

Group Type: EXPERIMENTAL

Cilostazol 100 mg Tablets

Intervention Type: DRUG

Cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours

Pletal® (cilostazol)

A single dose of cilostazol (Pletal® 1 x 100 mg tablet) administered after an overnight fast of at least 10 hours.

Group Type: EXPERIMENTAL

Cilostazol (Pletal®) 100 mg Tablets

Intervention Type: DRUG

Cilostazol (Pletal® 1 x 100mg tablet) administered after an overnight fast of at least 10 hours.

Interventions

Cilostazol 100 mg Tablets

Cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours

Intervention Type: DRUG

Cilostazol (Pletal®) 100 mg Tablets

Cilostazol (Pletal® 1 x 100mg tablet) administered after an overnight fast of at least 10 hours.

Intervention Type: DRUG

Other Intervention Names

Pletal®

Eligibility Criteria

Inclusion Criteria

• Healthy adults 18-55 years of age
• Non-smoking
• Non-pregnant (post-menopausal, surgically sterile or using effective contraceptive measures)
• No more than 15% plus or minus from ideal weight for subject's height and elbow breadth as defined by the Metropolitan Life Insurance Company Statistical Bulletin. Extrapolations, if required, to be conducted according to BASi Standard Operating Procedures
• Medically healthy on the basis of medical history and physical examination within 30 days prior to the start of the study
• Test results from blood chemistry, hematology, and urinalysis performed within 30days prior to the start of the study within clinically acceptable limits
• At screening, subjects must have blood pressure and pulse rate within the following ranges: Systolic blood pressure 90-140mmHg; Diastolic blood pressure 50-90mmHg; Pulse 45-100 bpm
• An acceptable electrocardiogram (EKG): sinus rhythm with no evidence of AV block or ischemic changes

Exclusion Criteria

• Prescription drug use (excluding hormonal contraceptives) within 14 days prior to drug administration, each period
• Aspirin ingestion within 7 days prior to drug administration, each period
• Use of any over-the-counter preparations, herbal remedies, and/or nutritional supplements within 7 days prior to drug administration, each period
• Consumption of grapefruit juice or grapefruit-containing products within 72 hours prior to drug administration , each period
• Consumption of alcohol within 24 hours prior to drug administration, each period
• Consumption of caffeine within 10 hours prior to drug administration, each period
• Female subjects must not be pregnant or nursing; and must be surgically sterile; one year post-menopausal; or on hormonal contraceptive agent(s), a diaphragm or condom with spermicidal foam or jelly, or IUD for at least three months prior to drug administration and agree to use the same method of contraception for at least 1 month after the last drug administration
• Subjects with a history or presence of significant organ system (cardiovascular, neurological, hepatic, hematopoietic, renal, pulmonary, endocrine, or gastrointestinal) disorders, or ongoing infectious diseases
• History of hypersensitivity or adverse reactions to cilostazol (Pletal®), or other related drugs
• Recent (12 month) history or evidence of alcoholism or drug abuse
• Positive results to Human Immunodeficiency Virus (HIV) or Hepatitis B surface Antigen (HBsAg) tests

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Mutual Pharmaceutical Company, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Mutual Pharmaceutical Company, Inc.

Principal Investigators

Dilip K Guha-Ray, M.D.

Role: PRINCIPAL_INVESTIGATOR

BASi Baltimore Clinical Research Unit

Related Links

http://www.fda.gov/opacom/7alerts.html

Recalls, Market Withdrawals and Safety Alerts

http://dailymed.nlm.nih.gov/dailymed/about.cfm

Daily Med - Posting of Recently Submitted Labeling to the FDA

Other Identifiers

11788

Identifier Type: -

Identifier Source: org_study_id